Thu 18 Oct 2018 09:43:47 PM CDT: This site is about to be upgraded to a new software release. During this upgrade you may experience interruptions or delays when entering information. We apologize for any inconvenience this may cause and thank you for your patience during this required update.
FDA Approves Bayer's New Class of Drug to Treeat Adults with PAH
First and Only Drug Approved in United States to Treat Two Forms of Pulmonary Hypertension
announced on Wednesday that the United States Food and Drug Administration
(FDA) has approved Adempas® (riociguat) tablets for the treatment of adults
with pulmonary arterial hypertension (PAH) and adults with persistent/recurrent
chronic thromboembolic pulmonary hypertension (CTEPH) to improve exercise
capacity, improve WHO functional class, and delay clinical worsening.